Purpose | Board Meetings Date | Announcement Date |
---|---|---|
Board Meeting | 19 Jul 2024 | 10 Jul 2024 |
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/07/2024 inter alia to consider and approve Intimation of Board Meeting -July 19 2024 The Company has submitted to the Stock Exchange the Outcome of Board Meeting held on July 19, 2024 Unaudited Financial Results for June 30, 2024 (As per BSE Announcement Dated on 19/07/2024) | ||
Board Meeting | 29 May 2024 | 22 May 2024 |
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Intimation of Board Meeting and recommendation of Final Dividend if any. Outcome of Board Meeting (As Per BSE Announcement Dated on: 29/05/2024) | ||
Board Meeting | 26 Mar 2024 | 26 Mar 2024 |
Outcome of the Board Meeting held on March 26, 2024 Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that based on the recommendations of the Nomination, Remuneration & Compensation Committee, the Board of Directors of the Company at its meeting held on March 26, 2024 at 11:00 A.M. (IST) and concluded at 11:40 A.M. (IST), appointed Dr. Harsh Mahajan (DIN: 00824227) and Ms. Shivpriya Nanda (DIN: 01313356), as an Additional Director (Non-Executive, Independent) on the Board of the Company w.e.f April 1, 2024 for an initial term of five (5) years i.e. upto March 31, 2029, subject to approval of the shareholders to be obtained within three (3) months hereof. Further, Mr. Srinivasan Sridhar (DIN: 00004272), Ms. Sudha Pillai (DIN: 02263950) and Dr. Ashok Misra (DIN: 00006051), Independent Directors of the Company shall complete their second term on March 31, 2024 and accordingly cease to be an Independent Director on Board of the Company with effect from the closing hours of March 31, 2024. The composition of the Board of Directors of the Company is in compliance with the requirements prescribed under the Companies Act, 2013 and SEBI Listing Regulations. Change in Independent Directors of the Company | ||
Board Meeting | 2 Feb 2024 | 23 Jan 2024 |
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 inter alia to consider and approve Board Meeting Intimation for unaudited standalone and consolidated financial results of the Company for the Quarter and Nine months ended December 31 2023 Unaudited Financial Results Q3 FY 2024 alongwith Limited Review Report (As Per BSE Announcement Dated on: 02/02/2024) | ||
Board Meeting | 27 Oct 2023 | 19 Oct 2023 |
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2023. Unaudited standalone & Consolidated financial Results for Q2 FY 2024 Change in Directors. Disclosure as per attachment. (As per BSE Announcement Dated on 27/10/2023) Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2023 published on October 28, 2023 in MINT (English) and HINDUSTAN (Hindi). (As per BSE Announcement Dated on 30/10/2023) |
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.